Læknablaðið - 15.04.2007, Side 37

FRÆÐIGREINARGREIN / HRÖRNUN í AUGNBOTNUM
félagslegu þjónustunni þar sem þetta fólk getur þá
búið lengur heima og bjargað sér sjálft. Að auki
stór bætir lyfið lífsgæði sjúklinga.
Heilbrigðisyfirvöld í Danmörku hafa ákveðið
að árið 2007 verði lyfið eingöngu notað á fimm
sjúkrahúsum og hafa þau þegar hafið meðferð
með Lucentis. I Svíþjóð hafa þegar á annan tug
stofnana hafið meðferð með Lucentis og gert er
ráð fyrir að þeim stofnunum muni fjölga á næstu
vikum. Ellihrörnun í augnbotnum veldur um
helmingi allrar blindu á íslandi. Þess er vænst að
leyfi til notkunar lyfsins á íslandi fáist á næstunni.
Heimildir
1. Kvanta A. New treatments for neovascular age-related
macular degeneration: when should we use them? Acta
Ophthalmol Scand 2007; 85:5.
2. la Cour M. Intravitreal VEGF-inhibitors: is Avastin((R)) a
generic substitute for Lucentis((R))? Acta Ophthalmol Scand
2007;85:2-4.
3. Virgili G, Do DV, Bressler NM, Menchini U. New therapies
for neovascular age-related macular degeneration: critical
appraisal of the current evidence. Acta Ophthalmol Scand
2007; 85:6-20.
4. Algvere PV, Marshall J, Seregard S. Age-related maculopathy
and the impact of blue light hazard. Acta Ophthalmol Scand
2006; 84:4-15.
5. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I,
Schlichtenbrede F, et al. Visual acuity change after intravitreal
bevacizumab for exudative age-related macular degeneration
in relation to subfoveal membrane type. Acta Ophthalmol
Scand 2007; 85:26.
6. Schneider U, Gelisken F, Inhoffen W. Natural course of
occult choroidal neovascularization in age-related macular
degeneration: development of classic lesions in fluorescein
angiography. Acta Ophthalmol Scand 2005; 83:141-7.
7. Jonas JB. Intravitreal triamcinolone acetonide for treatment
of intraocular oedematous and neovascular diseases. Acta
Ophthalmol Scand 2005; 83:645-63.
8. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim
RY, et al. Ranibizumab versus verteporfin for neovascular
age-related macular degeneration. N Engl J Med 2006; 355:
1432-44.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK,
Chung CY, et al. Ranibizumab for neovascular age-related
macular degeneration. N Engl J Med 2006; 355:1419-31.
10. Abraham P, Yue H, Shams N. PIER: Year 1 results of a phase
Illb study of ranibizumab efficacy and safety in choroidal
neovascularization due to age-related macular degeneration.
Abstract Cannes Retina Festival 2006.
11. Fung AE, Rosenfeld PJ, Uliafito CA, Michels S, Lalwani GA,
Feuer WJ. One year results of the PRONTO study: An OCT-
guided variable-dosing regimen with ranibizumab (Lucentis)
in neovascular AMD. Abstract Combined meeting: Club Jules
Gonin and The Retina Society, Cape Town, South Africa 2006.
12. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence
tomography: a key to the future management of patients with
diabetic macular oedema. Acta Ophthalmol Scand 2006; 84:
466-74.
13. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M,
Guyer DR. Pegaptanib for neovascular age-related macular
degeneration. N Engl J Med 2004; 351:2805-16.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T,
Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N
Engl J Med 2004; 350:2335-42.
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence
tomography findings after an intravitreal injection of
bevacizumab (avastin) for neovascular age-related macular
degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-5.
16. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA,
Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for
neovascular age-related macular degeneration. Ophthalmology
2006;113:363-72 e5.
17. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, E1
Haibi CP, Noureddin BN. Intravitreal bevacizumab for the
management of choroidal neovascularization in age-related
macular degeneration. Am J Ophthalmol 2006; 142:1-9.
18. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr., Scott
IU. Intravitreal bevacizumab for choroidal neovascularization
caused by AMD (IBeNA Study): results of a phase 1 dose-
escalation study. Invest Ophthalmol Vis Sci 2006; 47:4569-78.
19. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis
JL, Flynn HW Jr., et al. Short-term safety and efficacy of
intravitreal bevacizumab (Avastin) for neovascular age-
related macular degeneration. Retina 2006; 26:495-511.
20. Spaide RF, Laud K, Fine HF, Klancnik JM Jr., Meyerle CB,
Yannuzzi LA, et al. Intravitreal bevacizumab treatment
of choroidal neovascularization secondary to age-related
macular degeneration. Retina 2006; 26:383-90.
21. Aggio FB, Melo GB, Hofling-Lima AL, Eid Farah M.
Photodynamic therapy with verteporfm combined with
intravitreal injection of bevacizumab for exudative age-related
macular degeneration. Acta Ophthalmol Scand 2006; 84: 831-
3.
22. Bom Aggio F, Eid Farah M, Melo GB. Intravitreal
bevacizumab for occult choroidal neovascularization with
pigment epithelium detachment in age-related macular
degeneration. Acta Ophthalmol Scand 2006; 84:713-4.
23. Soliman W, Lund-Andersen H, Larsen M. Resolution
of subretinal haemorrhage and fluid after intravitreal
bevacizumab in aggressive peripapillary subretinal
neovascularization. Acta Ophthalmol Scand 2006; 84:707-8.
24. Gelisken F, Ziemssen F,Voelker M, Bartz-Schmidt KU. Retinal
pigment epithelial tear following intravitreal bevacizumab
injection for neovascular age-related macular degeneration.
Acta Ophthalmol Scand 2006; 84:833-4.
25. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin
AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the
treatment of proliferative diabetic retinopathy. Ophthalmology
2006; 113:1695 el-15.
26. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott
IU. Short-term results of intravitreal bevacizumab (Avastin)
on anterior segment neovascularization in neovascular
glaucoma. Acta Ophthalmol Scand 2006; 84:556-7.
27. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab
treatment of macular oedema due to central retinal vein
occlusion. Acta Ophthalmol Scand 2006; 84:555-6.
28. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU, la
Cour M. 14-year incidence, progression, and visual morbidity
of age-related maculopathy: the Copenhagen City Eye Study.
Ophthalmology 2005; 112:787-98.
29. la Cour M, Kiilgaard JF, Nissen MH. Age-related macular
degeneration: epidemiology and optimal treatment. Drugs
Aging 2002; 19:101-33.
30. Bjomsson OM, Syrdalen P, Bird AC, Peto T, Kinge B.
The prevalence of age-related maculopathy (ARM) in an
urban Norwegian population: the Oslo Macular study. Acta
Ophthalmol Scand 2006; 84:636-41.
31. Jónasson F, Arnarsson A, Peto T, Sasaki H, Sasaki K, Bird AC.
5-year incidence of age-related maculopathy in the Reykjavik
Eye Study. Ophthalmology 2005; 112:132-8.
32. Jónasson F, Arnarsson A, Sasaki H, Peto T, Sasaki K, Bird
AC. The prevalence of age-related maculopathy in iceland:
Reykjavik eye study. Arch Ophthalmol 2003; 121:379-85.
33. Amarsson A, Sverrisson T, Stefánsson E, Sigurðsson H, Sasaki
H, Sasaki K, et al. Risk factors for five-year incident age-
related macular degeneration: the Reykjavík Eye Study. Am J
Ophthalmol 2006; 142:419-28.
34. Fung AE, Rosenfeld PJ, Reichel E. The International
Intravitreal Bevacizumab Safety Survey: using the intemet to
assess dmg safety worldwide. Br J Ophthalmol 2006; 90:1344-9.
35. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual
impairment and falls in older adults: the Blue Mountains Eye
Study. J Am Geriatr Soc 1998; 46:58-64.
36. Klein BE, Klein R, Lee KE, Cruickshanks KJ. Performance-
based and self-assessed measures of visual function as related
to history of falls, hip fractures, and measured gait time. The
Beaver Dam Eye Study. Ophthalmology 1998; 105:160-4.
37. Ferrara N, Damico L, Shams N, Lowman H, Kim R.
Development of ranibizumab, an anti-vascular endothelial
growth factor antigen binding fragment, as therapy for
neovascular age-related macular degeneration. Retina 2006;
26:859-70.
38. Bakri SJ, Snyder MR, Pulido JS, Reid J, Singh RJ.
Pharmacokinetics of intravitreal bevacizumab (Avastin).
Abstract Cannes Retina Festival 2006.
39. Magnusson KP, Duan S, Sigurdsson H, Petursson H, Yang Z,
Zhao Y, et al. CFH Y402H confers similar risk of soft drusen
and both forms of advanced AMD. PLoS Med 2006; 3: e5.
40. Grisanti S, Tatar O, Gelisken F, Eckardt C, Lucke K,
Bartz-Schmidt KU. Histopathologic evaluation of choroidal
neovascular membranes following intravitreal bevacizumab
injection. Abstract Combined meeting: Club Jules Gonin and
The Retina Society, Cape Town, South Africa 2006.
Læknablaðið 2007/93 301